Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438482 | 1.00 | CYP3A4 (0.40) | CYP3A4ALDH1A1HPGDTDP1CES2 | |
| SCHEMBL6418213 | 0.86 | CYP3A4 (0.46) | CYP3A4ALDH1A1HPGDTDP1TRPA1 | |
| SCHEMBL15751295 | 0.81 | CYP3A4 (0.36) | CYP3A4ALDH1A1HPGDTDP1TRPA1 | |
| SCHEMBL707228 | 0.81 | CYP3A4 (0.55) | CYP3A4ALDH1A1HPGDTDP1TRPA1 | |
| SCHEMBL5266135 | 0.81 | CYP3A4 (0.36) | CYP3A4ALDH1A1HPGDTDP1TRPA1 | |
| SCHEMBL3550575 | 0.81 | CYP3A4 (0.36) | CYP3A4ALDH1A1HPGDTDP1TRPA1 | |
| SCHEMBL27480987 | 0.81 | CYP3A4 (0.36) | CYP3A4ALDH1A1HPGDTDP1TRPA1 | |
| SCHEMBL1595410 | 0.80 | CYP3A4 (0.54) | CYP3A4ALDH1A1HPGDTDP1CES2 | |
| SCHEMBL29662014 | 0.80 | CYP3A4 (0.54) | CYP3A4ALDH1A1HPGDTDP1CES2 | |
| SCHEMBL27480988 | 0.79 | CYP3A4 (0.35) | CYP3A4ALDH1A1HPGDTDP1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8609233-B2 | Intermediate transfer member | XEROX CORPORATION (US) | 2013-12-17 | — | — | US | claimed |
| US-20120288788-A1 | INTERMEDIATE TRANSFER MEMBER | XEROX CORPORATION (US) | 2012-11-15 | — | — | US | claimed |
| US-20120009371-A1 | INTERMEDIATE TRANSFER MEMBER | XEROX CORPORATION (US) | 2012-01-12 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| US-20240400575-A1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | UNIV BARCELONA (ES) | 2024-12-05 | — | — | US | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| EP-4433453-A1 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | Icagen, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240293362-A1 | Soluble Epoxide Hydrolase Inhibitors and Use Thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2024-09-05 | — | — | US | disclosed |
| WO-2023091554-A9 | NOVEL HETEROARYL-UREA COMPOUNDS AS KV7.2 INHIBITORS | ICAGEN, LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240150515-A1 | Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-09 | — | — | US | disclosed |
| WO-2003086563-A2 | DIABETES IMAGING PROBES | CARBOMER, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087045-A1 | NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS | 7TM PHARMA A/S (DK) | 2003-10-23 | — | — | WO | disclosed |
| CN-1444606-A | Olefin polymerization catalyst | DU PONT (US) | 2003-09-24 | — | — | CN | disclosed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002024420-A1 | METHOD FOR CHEMICAL TREATMENT OF A SURFACE | ATELIER REGIONAL DE CONSERVATION ARC-NUCLEART (FR) | 2002-03-28 | — | — | WO | disclosed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | disclosed |
| CN-1019578-B | The preparation method of quinoline carboxylic acid derivative | KANEBO LTD (JP) | 1992-12-23 | — | — | CN | disclosed |
| CN-88101987-A | Quinoline carboxylic acid derivative and the antiseptic-germicide that contains them | — | 1988-11-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | CYP3A4 18/4885ALDH1A1 2375/4885HPGD 3809/4885 |
| US-20240293362-A1 | Soluble Epoxide Hydrolase Inhibitors and Use Thereof | EPHX1, EPHX2, NCEH1 | CYP3A4 367/4885ALDH1A1 416/4885HPGD 88/4885 |
| US-20240400575-A1 | POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | CYP3A4 95/4885ALDH1A1 81/4885HPGD 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.